Article

AAO declares November Diabetic Eye Disease Awareness month

San Francisco-According to the American Academy of Ophthalmology (AAO), November is Diabetic Eye Disease Awareness month. People with diabetes are 25 times more likely to become blind than those who do not have the condition, according to the AAO.

San Francisco-According to the American Academy of Ophthalmology (AAO), November is Diabetic Eye Disease Awareness month. People with diabetes are 25 times more likely to become blind than those who do not have the condition, according to the AAO.

A retired New York police department detective, Anthony Sclafani, knew he had a vision problem when he could not see the red or green of the traffic lights. His Type II diabetes was what was causing the problem and thanks to laser treatment and monitoring blood sugar levels, his vision is now better than it has been for years.

"The careful control of blood sugar may prevent, and in some cases, even reverse early damage from diabetic retinopathy," says K. Bailey Freund, MD, a clinical correspondent for the academy and Sclafani's doctor. "With treatment and follow-up, we can minimize vision loss, or in some cases, restore vision to better than it was before treatment. A key factor for success is the patient's commitment to keeping his [or her] blood sugar tightly controlled through diet."

If caught early enough diabetic retinopathy can be controlled before vision loss occurs with injectable and oral medications, according to the AAO.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.